Product Description
to improve the management of type 2 diabetes mellitus. The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects such as the stimulation of insulin secretion and the inhibition of glucagon, when blood glucose is high. (Sourced from: https://ganlee.us/press-releases/gan-lee-pharmaceuticals-announces-u-s-fda-clearance/)
Mechanisms of Action: GLP-1 Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Gan & Lee Pharmaceuticals Shandong Co., Ltd. / Gan & Lee Pharmaceuticals Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Mexico, United States
Active Clinical Trial Count: 32
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Obesity|Overweight|Sleep Apnea, Obstructive|Type 2 Diabetes
Phase 2: Weight Loss
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07144098 |
GZR18-BWM-107 | P1 |
Recruiting |
Overweight|Obesity |
2026-07-12 |
2025-08-29 |
Primary Endpoints|Treatments |
|
NCT06737042 |
GL-GLP-2001 | P2 |
Completed |
Obesity|Overweight|Weight Loss |
2026-02-27 |
2026-07-17 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT07493057 |
GZR18-OSA-301 | P3 |
Not yet recruiting |
Sleep Apnea, Obstructive |
2027-11-14 |
19% |
2026-03-26 |
Primary Endpoints |
NCT06777238 |
Optimum 1 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2026-08-07 |
2025-11-26 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
|
CTR20255174 |
CTR20255174 | P1 |
Completed |
Healthy Volunteers |
2026-05-22 |
2026-07-26 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252678 |
CTR20252678 | P1 |
Completed |
Obesity |
2026-04-13 |
2026-07-26 |
||
CTR20251438 |
CTR20251438 | P1 |
Completed |
Type 2 Diabetes|Obesity|Overweight |
2025-12-31 |
2026-06-28 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20251570 |
CTR20251570 | P1 |
Completed |
Type 2 Diabetes |
2025-10-15 |
2026-01-11 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07141030 |
GZR18-BWM-106 | P1 |
Recruiting |
Overweight|Obesity |
2025-10-09 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT06974487 |
GZR102-T2D-101 | P1 |
Not yet recruiting |
Type 2 Diabetes|Overweight |
2025-09-30 |
2025-05-17 |
Primary Endpoints |
|
CTR20250966 |
CTR20250966 | P1 |
Completed |
Obesity|Type 2 Diabetes|Overweight |
2025-08-13 |
2026-03-08 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07119450 |
GZR18-BWM-105 | P1 |
Completed |
Overweight|Obesity |
2025-08-13 |
2025-11-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06778967 |
Optimum 2 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2026-12-11 |
2025-11-26 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT07055386 |
GZR102-T2D-201 | P2 |
Active, not recruiting |
Type 2 Diabetes |
2026-06-28 |
2025-11-22 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
|
CTR20252305 |
CTR20252305 | P2 |
Completed |
Type 2 Diabetes |
2026-04-27 |
2026-07-12 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06728124 |
GZR18-BWM-301 | P3 |
Active, not recruiting |
Obesity|Overweight |
2026-05-01 |
2025-11-26 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
CTR20244647 |
CTR20244647 | P3 |
Completed |
Obesity|Overweight |
2026-03-26 |
2026-07-12 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07501832 |
GZR18-OSA-302 | P3 |
Not yet recruiting |
Sleep Apnea, Obstructive |
2028-09-28 |
3% |
2026-04-01 |
Primary Endpoints|Treatments |
NCT07622810 |
BALANCE-OBS | P3 |
Not yet recruiting |
Obesity|Overweight |
2027-12-01 |
23% |
2026-06-04 |
Primary Endpoints|Treatments |
NCT07628985 |
BALANCE-DM2 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2027-10-01 |
8% |
2026-06-06 |
Primary Endpoints|Treatments |
NCT07292441 |
GZR18-BWM-303 | P3 |
Recruiting |
Overweight|Obesity |
2027-09-01 |
14% |
2026-03-12 |
|
NCT07150975 |
GZR18-BWM-302 | P3 |
Recruiting |
Overweight|Obesity |
2027-06-30 |
2025-11-26 |
||
NCT07128888 |
GZR18-BWM-104 | P1 |
Recruiting |
Obesity|Overweight |
2026-07-05 |
2025-11-26 |
Primary Endpoints|Treatments|Trial Status |
|
CTR20253278 |
CTR20253278 | P1 |
Completed |
Overweight|Type 2 Diabetes|Obesity |
2026-06-16 |
2026-06-21 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07355738 |
GZR18-OOO-108 | P1 |
Recruiting |
Obesity |
2026-05-20 |
88% |
2026-01-23 |